The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2021 | Auto-allo tandem SCT for myeloma
Nicolaus Kröger, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, outlines the results of a study (NCT00777998) investigating the safety and efficacy of the combination of auto-allo tandem stem cell transplantation (SCT) in patients with multiple myeloma, followed by maintenance therapy with low-dose thalidomide and donor lymphocyte infusions. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.
